nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-77EC08C3·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Cancer Research·Basis: Full text·Type: Diagnostic accuracy study

Technical feasibility of a long read, fourth generation sequencing platform in diagnostic profiling of clinical routine samples: a proof-of-concept study.

Vitale et al.Vitale, Colarossi, Russo et al.·2026·Pathologica·10.32074/1591-951x-1936 ↗

Primary claim

The adapted ONT workflow demonstrated high concordance rate in detecting clinically relevant molecular alterations on short-read fragments, achieving comparable accuracy with standardized second generation NGS platforms on tissue and liquid biopsy samples.

Tentative · ten specimens, one liquid biopsy, and no bidirectional accuracy estimates cannot establish comparable diagnostic accuracy
In brief

A useful MinION feasibility pilot whose ten-sample comparison and unresolved low-VAF workflow cannot establish comparable diagnostic accuracy.

ReliabilityCaveats4 of 4 checks completeRead the 3 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: Next generation sequencing (NGS) impacted on clinical algorithm of solid tumor patients. A heterogeneous series of NGS platforms have been implemented in clinical practice but challenging handling procedures, high technical costs, and scant affordability on sequencing diagnostic routine specimens can leave behind some patients who could benefit from target drugs. Here, we sought to evaluate technical feasibility of Oxford Nanopore Technologies (ONT) sequencing accurate identification of tumor-associated molecular alterations, in a pilot series of real-world samples.

METHODS: We developed a technical workflow adapting the SiRe® NGS panel, originally designed for Ion semiconductor sequencing, on MinION platform (Oxford nanopore technologies), a portable, cost effective long read sequencer. The SiRe® panel enables detection of ٥٦٨ clinically actionable somatic mutations across six key genes (EGFR, KRAS, NRAS, BRAF, cKIT, PDGFRα) relevant to targeted therapies in several solid tumors. We implemented a multiplexed assay using pooled and barcoded samples, processed on a single MinION flow cell. Performance was benchmarked from a pilot series of nine FFPE samples against Ion Torrent sequencing data. A single liquid biopsy sample was also analyzed testing accuracy of MinION technology.

RESULTS: The adapted ONT workflow demonstrated high concordance ratei in detecting clinically relevant molecular alterations on short-read fragments, achieving comparable accuracy with standardized second generation NGS platforms on tissue and liquid biopsy samples.

CONCLUSIONS: This proof of concept aimed to integrate ONT sequencing into molecular oncology workflows, providing practical, low-cost, and scalable alternative to conventional NGS platforms. The results support the potential of ONT technology to democratize access to precision oncology, particularly in laboratories with limited resources.

Key Claims

Primary finding · Tentative

The adapted ONT workflow demonstrated high concordance rate in detecting clinically relevant molecular alterations on short-read fragments, achieving comparable accuracy with standardized second generation NGS platforms on tissue and liquid biopsy samples.

Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

ten specimens, one liquid biopsy, and no bidirectional accuracy estimates cannot establish comparable diagnostic accuracy

Abstract, Results
Quote verified
Secondary · Tentative

A perfect match between MinION workflow and conventional short-read sequencing pipeline was identified. In detail, 14 single-nucleotide variants (SNVs) across all 10 samples, were confirmed by ONT sequencing.

one-directional recovery lacks ONT-only call, indel, precision, and independently verified low-VAF accounting

Results, paragraph 2
Quote verified
Secondary · Tentative

SNVs showing a variant allele frequency (VAF) ranging from 0.5% to 5.0% were consistently identified by the GATK MuTect2 pipeline and confirmed visually inspecting BAM files on Genomics Viewer (IGV) tool.

visual confirmation uses the same ONT reads and conflicts with the stated ≥5% filtering threshold

Results, paragraph 3
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Routine clinical specimens tested directly

The series includes nine archived FFPE NSCLC specimens and one GIST liquid-biopsy specimen, providing an intended-use feasibility setting rather than synthetic material alone.

↳ Study Design

#contribution

Specific MinION workflow is documented

The Methods identify the R10.4.1 flow cell, V14 barcoding chemistry, SUP basecalling model, GRCh38 alignment, and GATK calling tools, supporting technical reproducibility at the protocol level.

↳ MinION Protocol

#positioning

Limitations are explicitly identified

The Discussion recognises that the sample cannot establish robust performance and also identifies the narrow panel, missing clinical outcomes, and cross-platform reference differences.

↳ Discussion, limitations paragraph

Limitations

#methodological rigour

Low-VAF workflow remains internally inconsistent

The MinION Protocol states a VAF threshold of at least 5%, while Results report calls from 0.1% to 5.0% after visual inspection. The paper does not clearly identify which pipeline generated these calls or provide an independent confirmation strategy.

↳ MinION Protocol; Results, paragraph 3

#methodological rigour

Analytical accounting cannot be reconstructed

The Ion protocol describes eight pooled libraries although ten samples are reported, and a run used approximately 200 active pores despite an 800-pore minimum in Methods. These inconsistencies bear on the complete-concordance and feasibility claims.

↳ SiRe Protocol; MinION Protocol; Discussion, flow-cell comparison

#reporting

Accuracy claims exceed reported evidence

Fourteen recovered SNVs in ten samples are described as a perfect match and comparable accuracy without false-positive accounting, confidence intervals, indel performance, or a reported correlation statistic.

↳ Abstract, Results, paragraphs 2–3; Discussion

Does this match your read? Add your assessment ↓

Nabu Commentary

The paper demonstrates that adapted SiRe libraries can be sequenced on MinION across a small set of archived clinical specimens, giving the work a legitimate feasibility contribution. Its methodology is limited by the ten-sample spectrum, one liquid-biopsy case, shared amplicon libraries, absent diagnostic-agreement statistics, and unspecified independence of ONT interpretation. Most importantly, the MinION Protocol’s ≥5% VAF statement is not reconciled with Results reporting 0.1–5.0% detections after visual inspection. The Discussion acknowledges that the sample cannot prove robust performance, so conclusions about comparable accuracy, cost, scalability, and access should be narrowed and supported by larger validation data.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.2

Contribution
2.8

The study adds a specific adaptation of the six-gene SiRe panel to MinION using routine FFPE material and one liquid-biopsy sample. The advance remains incremental because ONT oncology sequencing is already established and the demonstration comprises only ten specimens.

Abstract, Methods; Study Design; Discussion

“A pilot series of 10 diagnostic samples”

Methodological Rigour
2.7

The study uses intended-use specimens and applies an Ion comparator across the series, but it reports no confusion matrix, precision estimates, or independent validation of low-frequency calls. The unresolved VAF threshold, library count, run-acceptance, blinding, and visual-review issues materially constrain execution.

Study Design; SiRe Protocol; MinION Protocol; Results, paragraphs 2–3

“Filtering chain was able to detect molecular alterations with variant allele fraction (VAF) ≥ 5%”

Reporting
2.6

The workflow and overall argument are followable, and the Discussion identifies several limitations. However, “perfect match,” “significant correlation,” and “comparable accuracy” are not accompanied by the quantitative agreement statistics or per-variant accounting required to support those formulations.

Abstract, Results, paragraphs 2–3; Discussion

“A perfect match between MinION workflow and conventional short-read sequencing pipeline was identified.”

Positioning
2.8

The Discussion identifies the small sample, narrow panel, absent clinical outcomes, and differing reference genomes as limitations. Its broader accuracy and access conclusions nevertheless proceed beyond the stated inability to establish robust technical performance.

Discussion, limitations and concluding paragraphs

“the sample set is inadequate to statistically prove robust technical performance”

Reliability

Caveats4 of 4 checks


Results checkNoted
  • SNVs showing a variant allele frequency (VAF) ranging from 0.5% to 5.0% were consistently identified by the GATK MuTect2 pipeline and confirmed visually inspecting BAM files on Genomics Viewer (IGV) tool: "Filtering chain was able to detect molecular alterations with variant allele fraction (VAF) ≥ 5% adopting the GATK HaplotypeCaller (germline alterations) and GATK Mutec2 (somatic variations) pipelines." (MinION Protocol) vs "Notably, SNVs showing a variant allele frequency (VAF) ranging from 0.5% to 5.0% were consistently identified by the GATK MuTect2 pipeline and confirmed visually inspecting BAM files on Genomics Viewer (IGV) tool. Notably, a visual inspection of the raw data using the IGV tool confirmed the detection of low-frequency genomic alterations, ranging from 0.1% to 5.0% MAF, identified by the SiRe™ MinION pipeline." (Results, final paragraph). The reported detection ranges extend below the stated ≥5% filtering threshold, but the text does not identify an alternative filter or provide call-level information from which to recompute the low-frequency detection result. → Effect on result unclear
Reporting and transparencyNoted

Reporting ambiguities concern the panel's six-versus-seven gene count, PromethION-versus-MinION naming, eight pooled libraries versus ten samples, the 800-pore criterion versus a 200-pore run, 24 versus 48 hours of sequencing, and the unit of median DNA concentration; none establishes a corrected accuracy or concordance result.

Conflict of interest: declared · Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: not stated

Reference IntegrityNoted

29 references in manuscript 28 of 28 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceMethodological
Route to useNamed
AdvanceExtends
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The workflow is a proof of concept shown working once on a small pilot of ten samples benchmarked against standard sequencing, without independent confirmation.

From the paper
“support the potential of ONT technology to democratize access to precision oncology, particularly in laboratories with limited resources”

The paper names molecular diagnostics laboratories, especially resource-limited ones, as the setting that would adopt this sequencing workflow for cancer profiling.

Pathway

Molecular pathology laboratories, especially resource-limited ones, adopt the low-cost ONT workflow for routine profiling of actionable cancer mutations in tissue and liquid biopsy samples.

Barrier

The pilot of only ten samples lacks statistical power and clinical outcome data, and optimized bioinformatic pipelines are still needed before routine diagnostic use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

    Weihua Zeng, S. Guo-Dong Li, Shuo Li, et al. · 2026 · Clinical medicine

    Primary claim

    MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3%

    Supported
    Evidence Score
    3.7±0.2
    Reliability
    Caveats
  2. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

    Cortes, Haiderali, Huang, et al. · 2023 · Basic medicine

    Primary claim

    Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab confers benefits in response and survival outcomes versus alternative neoadjuvant treatments for early-stage TNBC.

    Tentative
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Efficient differential expression analysis of large-scale single-cell transcriptomics data using Dreamlet

    2026 · Biological sciences

    Primary claim

    Designed for data from large cohorts, dreamlet is substantially faster and uses less memory than existing workflows, while supporting complex statistical models and controlling the false positive rate.

    Tentative
    Evidence Score
    4.0±0.2
    Reliability
    Caveats

How the rubric works →